8-K: Aquestive Anaphylm Faces FDA Deficiencies, Approval Delay Risk

Aquestive Therapeutics announced FDA identified deficiencies in its Anaphylm NDA, potentially delaying approval, while confirming strong cash position and global expansion plans.

Summary

• The U.S. Food and Drug Administration (FDA) identified deficiencies in Aquestive Therapeutics' New Drug Application (NDA) for Anaphylm (epinephrine) Sublingual Film, precluding discussion of labeling and post-marketing commitments.
• The FDA did not specify the deficiencies but confirmed its review is ongoing and that this notification does not reflect a final decision.
• Aquestive is actively working to understand and resolve the FDA's concerns prior to the scheduled PDUFA goal date of January 31, 2026.
• This development could result in a delay of the possible FDA approval for Anaphylm.
• The company is advancing its global strategy for Anaphylm, having initiated regulatory engagements in Canada, Europe, and the United Kingdom in 2025.
• Aquestive plans to seek regulatory approval for Anaphylm in Canada and Europe in 2026.
• The company reported approximately $120 million in cash and cash equivalents as of December 31, 2025.
• Aquestive believes its recent equity raise and current cash position provide sufficient capital to execute its current long-term strategy.
• The Anaphylm NDA submission is supported by a comprehensive clinical development program involving eleven studies with 967 total administrations across 411 subjects.
• Clinical studies demonstrated Anaphylm delivers a pharmacokinetic (PK) profile comparable to leading epinephrine auto-injectors and was generally well tolerated with a safety profile similar to epinephrine.
• The European Medicines Agency (EMA) provided positive feedback, indicating no further clinical trials are needed prior to regulatory approval submission in Europe.
• Aquestive expects to submit its New Drug Submission (NDS) to Health Canada in the first half of 2026 and its marketing authorization application in Europe in the second half of 2026.
• Feedback from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom is expected in the first quarter of 2026.

Sentiment

Score: 4

Explanation: The FDA deficiency notice and potential approval delay for Anaphylm are significant setbacks, despite the company's strong cash position and global expansion efforts. The unspecified nature of the deficiencies adds uncertainty to the regulatory pathway.

Positives

• Approximately $120 million in cash and cash equivalents as of December 31, 2025, providing sufficient capital for current long-term strategy.
• Ongoing global expansion strategy for Anaphylm, with regulatory engagements initiated in Canada, Europe, and the UK in 2025.
• Positive feedback from the European Medicines Agency (EMA) indicating no further clinical trials are needed prior to regulatory approval submission in Europe.
• Anaphylm's clinical development program demonstrated a pharmacokinetic (PK) profile comparable to leading epinephrine auto-injectors.
• Anaphylm was generally well tolerated with a safety profile similar to that of epinephrine.
• FDA confirmed its review of the Anaphylm NDA is ongoing and the notification does not reflect a final decision.

Negatives

• FDA identified deficiencies in the New Drug Application (NDA) for Anaphylm, precluding discussion of labeling and post-marketing commitments.
• The FDA did not specify the identified deficiencies, adding uncertainty.
• This development could result in a delay of the possible FDA approval of the NDA for Anaphylm.
• Further delays in communicating specific deficiencies may lead to a delay in potential approval.

Risks

• Delays or changes to the timing, cost, and success of product development activities and clinical trials for Anaphylm.
• Risk of delays in advancement of the regulatory approval process through the FDA for Anaphylm, or failure to receive FDA approval at all.
• Risk of FDA inspections of manufacturing and clinical study sites for Anaphylm.
• Risk of government shutdowns or actions reducing government workforces impacting FDA approval.
• Risk of the company's ability to generate sufficient clinical data for approval, including pharmacokinetic and pharmacodynamic (PK/PD) comparability submission for Anaphylm.
• Risks associated with the ability to address the FDA's comments on and identified deficiencies in the NDA, including the risk that the FDA may require additional clinical studies for approval of Anaphylm.
• Risk of the success of any competing products, including generics.
• Risks and uncertainties inherent in commercializing a new product (including technology risks, financial risks, market risks, implementation risks, and regulatory limitations).
• Risk of development of a sales and marketing capability for commercialization of Anaphylm, if approved by the FDA.
• Risks associated with the potential impact on the value of the company of the sale or outlicensing of products and product candidates, including Anaphylm.
• Risk of sufficient capital and cash resources, including sufficient access to available debt and equity financing, and revenues from operations, to satisfy all short-term and longer-term liquidity and cash requirements to support the growth strategy, and other cash needs, including to commence principal payments on 13.5% Senior Secured Notes in 2026, and to fund future clinical development and commercial activities for Anaphylm.
• Risk of the impact of obligations under the company's Purchase Agreement and Royalty Rights Agreement with third parties, each requiring payments of a portion of revenues, on the ability to contribute to funding operations and payment of principal and interest on debt.
• The risk of obligations under such Purchase Agreement and Royalty Rights Agreement impacting the ability to refinance 13.5% Senior Secured Notes.
• Risk that manufacturing capabilities will be insufficient to support demand of Anaphylm in the U.S. and abroad, if approved.
• Risk of eroding market share for Suboxone as a sunsetting product, which accounts for a substantial part of current operating revenue.
• Risk of default of debt instruments.
• Risks related to the outsourcing of certain sales, marketing, and other operational and staff functions to third parties.
• Risk of the rate and degree of market acceptance in the U.S. and abroad of Anaphylm, should it be approved.
• Risk associated with the size and growth of product markets.
• Risk associated with compliance with all FDA and other governmental and customer requirements for manufacturing facilities.
• Risks associated with intellectual property rights and infringement claims relating to products.
• Risk that patent applications for Anaphylm will not be timely issued, or issued at all, by the U.S. Patent and Trademark Office or, if issued, will be sufficient to provide long-term commercial success.
• Risk of unexpected patent developments.
• Risk of legislation and regulatory actions and changes in laws or regulations affecting the business, including relating to products and product candidates and product pricing, reimbursement or access therefor.
• Risk of loss of significant customers.
• Risks related to claims and legal proceedings against the company including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters.
• Risk of product recalls and withdrawals.
• Risks related to any disruptions in information technology networks and systems, including the impact of cybersecurity attacks.
• Risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements.
• Risk of adverse developments affecting the financial services industry.
• Risks related to inflation and changing interest rates.
• Risks related to the impact of pandemic diseases on the business.
• Risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial and market conditions and other unusual items.
• Risks related to uncertainty about presidential administration initiatives and their impact on the business, including imposition of government tariffs and other trade restrictions.

Future Outlook

Aquestive continues to believe Anaphylm represents a major step forward for people living with severe allergies and aims for its potential approval and subsequent launch in the U.S. and around the world. The company plans to submit for regulatory approval in Canada, Europe, and the UK in 2026, leveraging positive EMA feedback. Management believes the current capital, including a recent equity raise, is sufficient to complete the Anaphylm approval and launch processes in the U.S., if approved, while progressing Anaphylm in other key international markets.

Management Comments

• "As part of its ongoing review of the Company’s NDA for Anaphylm, the FDA notified us that it had identified deficiencies in the NDA that preclude discussion of labeling and post-marketing commitments at this time." Dan Barber, President and Chief Executive Officer of Aquestive.
• "Although the notification did not specify the deficiencies, Aquestive is working to understand and resolve the concerns." Dan Barber.
• "While we await further information from the FDA, we remain confident about Anaphylm and its potential to be the first and only FDA-approved sublingual film." Dan Barber.
• "Designed to be easy-to-use, fast-acting, and highly portable, we continue to believe Anaphlym represents a major step forward for people living with severe allergies." Dan Barber.
• "We are advancing our global expansion of Anaphylm with plans to submit for regulatory approval in Canada, Europe, and the United Kingdom in 2026." Dan Barber.
• "We believe our long-term growth strategy remains compelling with the potential approval and subsequent launch of Anaphylm in the U.S. and around the world." Dan Barber.
• "With the recent equity raise and our current cash position, we also believe that we have the necessary capital to execute on our current growth strategy." Dan Barber.

Industry Context

Anaphylm aims to be the first and only FDA-approved sublingual film for severe allergic reactions, positioning Aquestive to offer a non-invasive, easy-to-use, fast-acting, and highly portable alternative to existing epinephrine auto-injectors. This could significantly disrupt the current standard of care for anaphylaxis treatment, which primarily relies on injectable devices. The company's aggressive global expansion strategy indicates a broad market ambition beyond the U.S., seeking to address critical unmet needs in severe allergy management worldwide.

Comparison to Industry Standards

• Anaphylm's clinical development program demonstrated a pharmacokinetic (PK) profile comparable to the leading epinephrine auto-injectors.
• Anaphylm was generally well tolerated and had a safety profile similar to that of epinephrine.

Stakeholder Impact

• Shareholders: Potential negative impact due to uncertainty and delay in Anaphylm approval, which could affect stock price and future revenue projections.
• Patients with severe allergies: Potential delay in access to a novel, non-invasive epinephrine treatment.
• Employees: Continued focus on resolving FDA issues and advancing global strategy, with U.S. sales force hiring contingent on approval.

Next Steps

• Aquestive is working to understand and resolve the FDA's concerns regarding the Anaphylm NDA prior to the PDUFA goal date of January 31, 2026.
• The company expects to submit its New Drug Submission (NDS) to Health Canada in the first half of 2026.
• The company expects to receive feedback from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom in the first quarter of 2026.
• The company expects to submit its marketing authorization application in Europe in the second half of 2026.
• The company intends to hire its U.S. sales force following approval, if granted by the FDA, and continues to advance other pre-commercial activities for Anaphylm.

Key Dates

Recommendation

While the FDA deficiency is a significant negative, the company has a strong cash position and is actively pursuing global regulatory approvals, which could provide alternative pathways for Anaphylm. The FDA's statement that the review is ongoing and not a final decision leaves room for resolution. Investors should hold to see how the company addresses the FDA's concerns and progresses its international strategy.

Keywords

Aquestive Therapeutics, AQST, Anaphylm, epinephrine, sublingual film, FDA, New Drug Application, NDA, PDUFA, severe allergies, anaphylaxis, pharmaceutical, drug approval, regulatory review, cash position, global expansion, Canada, Europe, United Kingdom, clinical trials, PK profile, EMA, Health Canada, MHRA